Extension of the thrombolytic time window with minocycline in experimental stroke.
about
Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic StrokeVascular protection to increase the safety of tissue plasminogen activator for strokeRecommendations for preclinical research in hemorrhagic transformationEvaluation of combination therapy in animal models of cerebral ischemiaMutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat strokeProfile of minocycline neuroprotection in bilirubin-induced auditory system dysfunctionCombination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.Genome response to tissue plasminogen activator in experimental ischemic strokeProton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDSPreclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing.Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke.Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of miceMinocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic ratsThe science of stroke: mechanisms in search of treatments.Prehospital stroke care: new prospects for treatment and clinical researchA 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke modelImproving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in miceHigh-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia.Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery.Minocycline development for acute ischemic strokeMatrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic strokeNormobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhageBreaking out from the neuroprotective logjam: combined treatment with remote ischemic conditioning and minocycline in the prehospital settingMinocycline improves functional outcomes, memory deficits, and histopathology after endovascular perforation-induced subarachnoid hemorrhage in rats.Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke.Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke.Mixed cerebrovascular disease and the future of stroke prevention.Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental strokeThe neurovascular unit and combination treatment strategies for strokeNeuroprotective effects of adjunctive treatments for acute stroke thrombolysis: a review of clinical evidence.Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia.Does inhibiting Sur1 complement rt-PA in cerebral ischemia?Blood-brain barrier disruption after cardiac surgery.Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocyclineMatrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.
P2860
Q26766038-2490CAC9-12C3-4279-8972-5DA161F89CBAQ26824338-AD5F4AF3-182A-4D8A-B62E-B5E344444BCCQ27024324-1DD6A98A-1D9C-432A-A691-FAC5F1059539Q27025781-5AFDFD18-5FDC-49D1-9B0F-BC2AB297D39BQ28742609-E127F83B-BAA3-46A2-87FA-9594D7B047C3Q30471494-667B0C78-79C2-4421-9E24-725E53D8F6E6Q33482531-0E115916-6291-4A76-88D3-ACC970414F52Q33560492-01CB35BC-215E-4CCB-86BF-EC40DE4566B0Q33580220-236D79F5-BA6D-4B2E-8F43-5289DCA27606Q33729402-1B80A63A-33E9-46C1-AFAA-FD7598586066Q33889047-ED9C1849-4CAE-4FB1-A83F-D54D54B72757Q34006140-9D55C45F-431C-4AB1-85B1-7E59E7774101Q34079940-871BA74D-3E56-4F45-8DE2-26F4BDD10544Q34126485-D07E511C-3928-4520-B804-542EB7D808D6Q34212337-577D9933-1CE0-48B5-8F45-D82D1098C1AAQ34360614-3D4B146F-799A-42CA-9706-003F27B8547FQ34377030-2E5C79D5-0255-4E80-B2E4-B12F6717BF4EQ34659673-760F4394-2A2D-4C4A-B8D9-9DE4CE93F150Q34734410-33D51C36-A568-4EF7-A32A-4EA3A32456B5Q34768858-1C98DFB4-1060-4A0A-A9FE-16269F6A20D3Q35120831-51F667AC-35D5-45CB-A591-EB11203BE1DCQ35202559-E0E9CA55-539F-4494-BD4B-C8A9DF29D193Q35234799-02E44DE1-CC0D-4C16-BCAB-101AE849F965Q35554378-D0561519-7A92-4808-A479-8323577394E1Q35567319-2136C5D0-E11D-481A-A964-63C9CD08D5AAQ35581074-CD97DE03-B8EC-418C-9710-18A75A50FE24Q35584528-5D395C52-9FE4-417C-9A94-CFF0ACED2DFBQ35606184-0B3DB1AA-B228-4FC0-B024-4F5137BAB624Q35779826-E857D46C-4A56-42FA-9C7E-E592D961995DQ35996183-87985B2A-C144-445A-BF27-135AB61258F5Q36025087-3F52335F-D570-4463-B312-56C6F4C5874AQ36043123-70C2A5C1-EB18-4212-BD2A-0FEA931DB82DQ36104426-C0C52992-F20E-4BC9-AC3A-F1B6B7B5728BQ36124038-3FD74048-2445-4596-A090-0E9AF89E6149Q36256704-97E87356-D73F-4854-AB93-DC9C017685EFQ36405496-1D907434-ED2B-4F73-9E4A-236FA1FA9A44Q36426567-9B092275-6417-43E3-83DB-F0A465D9B966Q36431467-D500A31A-1CD5-45F8-9006-3290E123B947Q36514428-1FC38A44-031C-42F0-9BF2-EEC5B335DA92Q36736442-99D9C793-D29C-4554-B12A-79FCD165DC74
P2860
Extension of the thrombolytic time window with minocycline in experimental stroke.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Extension of the thrombolytic time window with minocycline in experimental stroke.
@en
type
label
Extension of the thrombolytic time window with minocycline in experimental stroke.
@en
prefLabel
Extension of the thrombolytic time window with minocycline in experimental stroke.
@en
P2093
P2860
P1433
P1476
Extension of the thrombolytic time window with minocycline in experimental stroke
@en
P2093
Anna Rosell
Kenneth J Rhodes
Xiaoying Wang
Yoshihiro Murata
P2860
P304
P356
10.1161/STROKEAHA.108.514026
P407
P577
2008-10-16T00:00:00Z